Ability Biologics
Allison Nixon, PhD, currently serves as the Director of Platform Sciences at Ability Biologics since January 2025. Prior to this, Allison held roles as Associate Director and Principal Scientist at AlivaMab Biologics from May 2022 to December 2024 and Lead Biology at Phenomic AI from May 2018 to May 2022. Allison completed a PhD in Molecular Genetics at the University of Toronto, where the thesis focused on integrins as mediators of cell state and tumor heterogeneity. During the doctoral research, Allison pioneered three independent projects involving the development of human synthetic antibodies, CRISPR gene editing, and genetic barcoding technology for cancer models. Additional experience includes an internship at the Centre for the Commercialization of Antibodies and Biologics and a co-op position at McMaster University, where Allison earned a Bachelor of Science with a specialization in Genetics.
This person is not in any teams
This person is not in any offices
Ability Biologics
1 followers
Our Mission: Develop innovative, targeted, immune modulating biotherapeutics to address unmet medical needs in patients with cancer and autoimmune diseases. The premier biotherapeutic targeting company Our powerful AbiLeap™ discovery engine combines massively parallel, continuously learning AI with an extensive database of antigen-antibody interactions to generate fully human, IgG-based multispecific antibodies of exquisite selectivity and affinity. The antibodies respond to environmental signals within the cellular microenvironment, generating logic-gated therapeutics. We are dedicated to developing the most potent and selective antibody therapeutics for areas of great unmet need.